References
- Bray F, Laversanne M, Sung H, Ferlay J, Siegel RL, Soerjomataram I,
Jemal A. Global cancer statistics 2022: GLOBOCAN estimates of
incidence and mortality worldwide for 36 cancers in 185 countries. CA
Cancer J Clin. 2024 May-Jun;74(3):229-263. doi: 10.3322/caac.21834.
- Olukunle OF, Omoboyede V, Chukwuemeka PO. Network pharmacology and
molecular docking-based identification of drug candidates and key
targets of Allium sativum for colorectal cancer treatment. J Biomol
Struct Dyn. 2024 Jun;42(9):4442-4455. doi:
10.1080/07391102.2023.2220823.
- Ansa BE, Alema-Mensah E, Sheats JQ, Mubasher M, Akintobi TH.
Colorectal Cancer Knowledge and Screening Change in African Americans:
Implementation Phase Results of the EPICS Cluster RCT. AJPM Focus.
2023 Jun 13;2(4):100121. doi: 10.1016/j.focus.2023.100121.
- Allemani C, Matsuda T, Di Carlo V, Harewood R, Matz M, Nikšić M,
Bonaventure A, Valkov M, Johnson CJ, Estève J, Ogunbiyi OJ, Azevedo E
Silva G, Chen WQ, Eser S, Engholm G, Stiller CA, Monnereau A, Woods
RR, Visser O, Lim GH, Aitken J, Weir HK, Coleman MP; CONCORD Working
Group. Global surveillance of trends in cancer survival 2000-14
(CONCORD-3): analysis of individual records for 37 513 025 patients
diagnosed with one of 18 cancers from 322 population-based registries
in 71 countries. Lancet. 2018 Mar 17;391(10125):1023-1075. doi:
10.1016/S0140-6736(17)33326-3.
- Modest DP, Pant S, Sartore-Bianchi A. Treatment sequencing in
metastatic colorectal cancer. Eur J Cancer. 2019 Mar;109:70-83. doi:
10.1016/j.ejca.2018.12.019.
- Xu R, Wang W, Zhu B, Lin X, Ma D, Zhu L, Zhao Q, Nie Y, Cai X, Li Q,
Fang W, Li H, Wang N, Chen Y, Peng C, Fang H, Shen L. Disease
characteristics and treatment patterns of Chinese patients with
metastatic colorectal cancer: a retrospective study using medical
records from China. BMC Cancer. 2020 Feb 18;20(1):131. doi:
10.1186/s12885-020-6557-5.
- Ren W, Fang Y, He Y, Ren Y, Wang M, Xu A, Ruan J, Tao Q. Efficacy and
Safety of Programmed Death 1/Programmed Death-Ligand 1 Plus Cytotoxic
T-Lymphocyte-Associated Antigen 4 Inhibitors for Advanced or
Metastatic Non-Small Cell Lung Cancer: A Meta-analysis Based on
Randomized Controlled Trials. Ther Drug Monit. 2024 Aug
1;46(4):422-433. doi: 10.1097/FTD.0000000000001228.
- Elez E, Cubillo A, Alfonso PG, Middleton MR, Chau I, Alkuzweny B,
Alcasid A, Zhang X, Van Cutsem E. Binimetinib in combination with
nivolumab or nivolumab and ipilimumab in patients with previously
treated microsatellite-stable metastatic colorectal cancer with RAS
mutations in an open-label phase 1b/2 study. BMC Cancer. 2024 Apr
11;24(1):446. doi: 10.1186/s12885-024-12153-5.
- Wang ZX, Peng J, Liang X, Cheng Y, Deng Y, Chen K, Zhang M, Zhang J,
Wang W, Cao B, Jin Y, Sun M, Lin Y, Luo S, Li Z, Yang L, Ke Y, Yu H,
Li J, Wang Q, Zhu J, Wang F, Xu RH. First-line serplulimab in
metastatic colorectal cancer: Phase 2 results of a randomized,
double-blind, phase 2/3 trial. Med. 2024 Sep 13;5(9):1150-1163.e3.
doi: 10.1016/j.medj.2024.05.009.
- Zhong W, Yu Z, Zhan J, Yu T, Lin Y, Xia ZS, Yuan YH, Chen QK.
Association of serum levels of CEA, CA199, CA125, CYFRA21-1 and CA72-4
and disease characteristics in colorectal cancer. Pathol Oncol Res.
2015 Jan;21(1):83-95. doi: 10.1007/s12253-014-9791-9.
- Schrock AB, Ouyang C, Sandhu J, Sokol E, Jin D, Ross JS, Miller VA,
Lim D, Amanam I, Chao J, Catenacci D, Cho M, Braiteh F, Klempner SJ,
Ali SM, Fakih M. Tumor mutational burden is predictive of response to
immune checkpoint inhibitors in MSI-high metastatic colorectal cancer.
Ann Oncol. 2019 Jul 1;30(7):1096-1103. doi: 10.1093/annonc/mdz134.
- Wang F, Zhao Q, Wang YN, Jin Y, He MM, Liu ZX, Xu RH. Evaluation of
POLE and POLD1 Mutations as Biomarkers for Immunotherapy Outcomes
Across Multiple Cancer Types. JAMA Oncol. 2019 Oct 1;5(10):1504-1506.
doi: 10.1001/jamaoncol.2019.2963.
- Li Y, Liang L, Dai W, Cai G, Xu Y, Li X, Li Q, Cai S. Prognostic
impact of programed cell death-1 (PD-1) and PD-ligand 1 (PD-L1)
expression in cancer cells and tumor infiltrating lymphocytes in
colorectal cancer. Mol Cancer. 2016 Aug 24;15(1):55. doi:
10.1186/s12943-016-0539-x.
- Rozek LS, Schmit SL, Greenson JK, Tomsho LP, Rennert HS, Rennert G,
Gruber SB. Tumor-Infiltrating Lymphocytes, Crohn’s-Like Lymphoid
Reaction, and Survival From Colorectal Cancer. J Natl Cancer Inst.
2016 May 12;108(8):djw027. doi: 10.1093/jnci/djw027.
- Guren MG. The global challenge of colorectal cancer. Lancet
Gastroenterol Hepatol. 2019 Dec;4(12):894-895. doi:
10.1016/S2468-1253(19)30329-2.
- Kroemer M, Turco C, Spehner L, Viot J, Idirène I, Bouard A, Renaude E,
Deschamps M, Godet Y, Adotévi O, Limat S, Heyd B, Jary M, Loyon R,
Borg C. Investigation of the prognostic value of CD4 T cell subsets
expanded from tumor-infiltrating lymphocytes of colorectal cancer
liver metastases. J Immunother Cancer. 2020 Nov;8(2):e001478. doi:
10.1136/jitc-2020-001478.
- Tamai K, Okamura S, Makino S, Yamamura N, Fukuchi N, Ebisui C, Inoue
A, Yano M. C-reactive protein/albumin ratio predicts survival after
curative surgery in elderly patients with colorectal cancer. Updates
Surg. 2022 Feb;74(1):153-162. doi: 10.1007/s13304-021-01011-9.
- Petracci E, Passardi A, Biggeri A, Valgiusti M, Monti M, Frassineti
GL, Nanni O, Scarpi E. Baseline and Longitudinal
Neutrophil-to-Lymphocyte Ratio as Prognostic Factor for Metastatic
Colorectal Cancer: A Secondary Analysis of the ITACa Randomized Trial.
JCO Precis Oncol. 2024 Jan;8:e2300256. doi: 10.1200/PO.23.00256.
- Ergen ŞA, Barlas C, Yıldırım C, Öksüz DÇ. Prognostic Role of
Peripheral Neutrophil-Lymphocyte Ratio (NLR) and Platelet-Lymphocyte
Ratio (PLR) in Patients with Rectal Cancer Undergoing Neoadjuvant
Chemoradiotherapy. J Gastrointest Cancer. 2022 Mar;53(1):151-160. doi:
10.1007/s12029-020-00578-7.
- Eisenhauer EA, Therasse P, Bogaerts J, Schwartz LH, Sargent D, Ford R,
Dancey J, Arbuck S, Gwyther S, Mooney M, Rubinstein L, Shankar L, Dodd
L, Kaplan R, Lacombe D, Verweij J. New response evaluation criteria in
solid tumours: revised RECIST guideline (version 1.1). Eur J Cancer.
2009 Jan;45(2):228-47. doi: 10.1016/j.ejca.2008.10.026.
- Chibaudel B, Maindrault-Gœbel F, Bachet JB, Louvet C, Khalil A, Dupuis
O, Hammel P, Garcia ML, Bennamoun M, Brusquant D, Tournigand C, André
T, Arbaud C, Larsen AK, Wang YW, Yeh CG, Bonnetain F, de Gramont A.
PEPCOL: a GERCOR randomized phase II study of nanoliposomal irinotecan
PEP02 (MM-398) or irinotecan with leucovorin/5-fluorouracil as
second-line therapy in metastatic colorectal cancer. Cancer Med. 2016
Apr;5(4):676-83. doi: 10.1002/cam4.635.
- Kalra AV, Kim J, Klinz SG, Paz N, Cain J, Drummond DC, Nielsen UB,
Fitzgerald JB. Preclinical activity of nanoliposomal irinotecan is
governed by tumor deposition and intratumor prodrug conversion. Cancer
Res. 2014 Dec 1;74(23):7003-13. doi: 10.1158/0008-5472.
- Wang JX, Wu HL, Zhu M, Zhou R. Role of Anti-Epidermal Growth Factor
Receptor Therapy Compared with Anti-Vascular Endothelial Growth Factor
Therapy for Metastatic Colorectal Cancer: an Update Meta-Analysis of
Randomized Clinical Trials. Pathol Oncol Res. 2020 Jan;26(1):159-166.
doi: 10.1007/s12253-017-0365-5.
- Liang X, Shen J. Impact of KRAS mutation status on outcomes of
metastatic colorectal cancer treated with anti-angiogenic agents: a
meta-analysis. J Chemother. 2020 Feb;32(1):41-48. doi:
10.1080/1120009X.2019.1692282.
- Lordick F, Thuss-Patience P, Bitzer M, Maurus D, Sahin U, Türeci Ö.
Immunological effects and activity of multiple doses of zolbetuximab
in combination with zoledronic acid and interleukin-2 in a phase 1
study in patients with advanced gastric and gastroesophageal junction
cancer. J Cancer Res Clin Oncol. 2023 Aug;149(9):5937-5950. doi:
10.1007/s00432-022-04459-3.
- Ricciuti B, Lamberti G, Andrini E, Genova C, De Giglio A, Bianconi V,
Sahebkar A, Chiari R, Pirro M. Antibody-drug conjugates for lung
cancer in the era of personalized oncology. Semin Cancer Biol. 2021
Feb;69:268-278. doi: 10.1016/j.semcancer.2019.12.024.
- Hutchins G, Southward K, Handley K, Magill L, Beaumont C, Stahlschmidt
J, Richman S, Chambers P, Seymour M, Kerr D, Gray R, Quirke P. Value
of mismatch repair, KRAS, and BRAF mutations in predicting recurrence
and benefits from chemotherapy in colorectal cancer. J Clin Oncol.
2011 Apr 1;29(10):1261-70. doi: 10.1200/JCO.2010.30.1366.
- Fan H, Bai L, Bai K. Longitudinal change of circulating tumor cell
level and its relationship with immune checkpoint inhibitor-based
treatment benefits in unresectable, metastatic colorectal cancer
patients. Scand J Clin Lab Invest. 2023 Jul;83(4):227-233. doi:
10.1080/00365513.2023.2204404.
- Andre T, Amonkar M, Norquist JM, Shiu KK, Kim TW, Jensen BV, Jensen
LH, Punt CJA, Smith D, Garcia-Carbonero R, Sevilla I, De La
Fouchardiere C, Rivera F, Elez E, Diaz LA Jr, Yoshino T, Van Cutsem E,
Yang P, Farooqui M, Le DT. Health-related quality of life in patients
with microsatellite instability-high or mismatch repair deficient
metastatic colorectal cancer treated with first-line pembrolizumab
versus chemotherapy (KEYNOTE-177): an open-label, randomised, phase 3
trial. Lancet Oncol. 2021 May;22(5):665-677. doi:
10.1016/S1470-2045(21)00064-4.
- Hedrick CC, Malanchi I. Neutrophils in cancer: heterogeneous and
multifaceted. Nat Rev Immunol. 2022 Mar;22(3):173-187. doi:
10.1038/s41577-021-00571-6.
- Shaul ME, Fridlender ZG. Tumour-associated neutrophils in patients
with cancer. Nat Rev Clin Oncol. 2019 Oct;16(10):601-620. doi:
10.1038/s41571-019-0222-4.
- Jaillon S, Ponzetta A, Di Mitri D, Santoni A, Bonecchi R, Mantovani A.
Neutrophil diversity and plasticity in tumour progression and therapy.
Nat Rev Cancer. 2020 Sep;20(9):485-503. doi:
10.1038/s41568-020-0281-y.
- Wu Y, Ma J, Yang X, Nan F, Zhang T, Ji S, Rao D, Feng H, Gao K, Gu X,
Jiang S, Song G, Pan J, Zhang M, Xu Y, Zhang S, Fan Y, Wang X, Zhou J,
Yang L, Fan J, Zhang X, Gao Q. Neutrophil profiling illuminates
anti-tumor antigen-presenting potency. Cell. 2024 Mar
14;187(6):1422-1439.e24. doi: 10.1016/j.
- Schernberg A, Blanchard P, Chargari C, Deutsch E. Neutrophils, a
candidate biomarker and target for radiation therapy? Acta Oncol. 2017
Nov;56(11):1522-1530. doi: 10.1080/0284186X.
- Mei Z, Shi L, Wang B, Yang J, Xiao Z, Du P, Wang Q, Yang W. Prognostic
role of pretreatment blood neutrophil-to-lymphocyte ratio in advanced
cancer survivors: A systematic review and meta-analysis of 66 cohort
studies. Cancer Treat Rev. 2017 Jul;58:1-13. doi:
10.1016/j.ctrv.2017.05.005.